United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$417.57 USD
+7.70 (1.88%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $419.09 +1.52 (0.36%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
UTHR 417.57 +7.70(1.88%)
Will UTHR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for UTHR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UTHR
Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?
Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?
UTHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals
Why Is United Therapeutics (UTHR) Up 11.9% Since Last Earnings Report?
Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?
Other News for UTHR
Director’s Major Stock Sale at United Therapeutics!
UTHR forms Golden Cross on September 18
Insider Sell: Judy Olian Sells Shares of United Therapeutics Corp (UTHR)
UTHR forms 180 Bullish Setup on September 17
UTHR falls 1.28% on September 16, leaving the technical picture intact